List of Evotaz drug patents

Evotaz is owned by Bristol-Myers Squibb.

Evotaz contains Atazanavir Sulfate; Cobicistat.

Evotaz has a total of 2 drug patents out of which 0 drug patents have expired.

Evotaz was authorised for market use on 29 January, 2015.

Evotaz is available in tablet;oral dosage forms.

Evotaz can be used as treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase.

The generics of Evotaz are possible to be released after 06 October, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148374 BRISTOL-MYERS SQUIBB Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 BRISTOL-MYERS SQUIBB Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

Drugs and Companies using ATAZANAVIR SULFATE; COBICISTAT ingredient

Market Authorisation Date: 29 January, 2015

Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase

Dosage: TABLET;ORAL

How can I launch a generic of EVOTAZ before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in